Indication
Blasts 20 Percent or Less of Peripheral Blood White Cells
1 clinical trial
1 product
Clinical trial
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic DisordersStatus: Recruiting, Estimated PCD: 2025-11-30
Product
Ruxolitinib